Cannara Historical Financial Ratios
LOVE Stock | CAD 0.70 0.02 2.78% |
Cannara Biotech is presently reporting on over 80 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 55.3 will help investors to properly organize and evaluate Cannara Biotech financial condition quickly.
Cannara |
About Cannara Financial Ratios Analysis
Cannara BiotechFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cannara Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cannara financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cannara Biotech history.
Cannara Biotech Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cannara Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cannara Biotech sales, a figure that is much harder to manipulate than other Cannara Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Most ratios from Cannara Biotech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cannara Biotech current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Cannara Biotech's Capex To Operating Cash Flow is fairly stable compared to the past year. PFCF Ratio is likely to climb to 20.01 in 2024, whereas PTB Ratio is likely to drop 0.66 in 2024.
2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 67.52 | 58.21 | 55.3 | PTB Ratio | 1.12 | 0.7 | 0.66 |
Cannara Biotech fundamentals Correlations
Click cells to compare fundamentals
Cannara Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cannara Biotech fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 26.57 | 7.64 | 3.3 | 1.56 | 0.75 | 0.71 | |
Ptb Ratio | 2.32 | 1.77 | 2.03 | 1.12 | 0.7 | 0.66 | |
Days Sales Outstanding | 44.17 | 63.65 | 87.76 | 67.52 | 58.21 | 55.3 | |
Book Value Per Share | 0.54 | 0.84 | 0.76 | 0.89 | 0.98 | 0.56 | |
Operating Cash Flow Per Share | (0.1) | (0.13) | (0.0274) | (0.0693) | 0.0609 | 0.12 | |
Stock Based Compensation To Revenue | 0.31 | 0.0195 | 0.00975 | 0.0306 | 0.0242 | 0.023 | |
Capex To Depreciation | 3.41 | 10.27 | 3.95 | 2.0 | 1.18 | 1.12 | |
Pb Ratio | 2.32 | 1.77 | 2.03 | 1.12 | 0.7 | 0.66 | |
Ev To Sales | 28.59 | 8.39 | 4.31 | 2.28 | 1.26 | 1.2 | |
Free Cash Flow Per Share | (0.42) | (0.25) | (0.43) | (0.0497) | 0.0357 | 0.0375 | |
Roic | (0.18) | (0.25) | 0.004611 | 0.0396 | 0.0948 | 0.11 | |
Inventory Turnover | 0.59 | 0.91 | 0.98 | 0.89 | 1.3 | 0.7 | |
Net Income Per Share | (0.19) | (0.0404) | 0.0263 | 0.0778 | 0.0715 | 0.0751 | |
Days Of Inventory On Hand | 616.86 | 402.27 | 374.25 | 410.49 | 281.49 | 201.94 | |
Payables Turnover | 0.48 | 1.09 | 2.17 | 3.38 | 5.28 | 5.54 | |
Sales General And Administrative To Revenue | 3.16 | 0.36 | 0.24 | 0.19 | 0.16 | 0.15 | |
Capex To Revenue | 3.46 | 1.83 | 0.43 | 0.17 | 0.0914 | 0.0868 | |
Pocfratio | (7.27) | (62.15) | (19.47) | 16.42 | 5.73 | 6.02 | |
Interest Coverage | (9.0) | 0.12 | 1.91 | 2.24 | 2.33 | 2.45 | |
Capex To Operating Cash Flow | (0.95) | (14.85) | (2.54) | 1.82 | 0.7 | 0.73 | |
Pfcf Ratio | (3.74) | (3.92) | (5.49) | (20.1) | 19.06 | 20.01 | |
Days Payables Outstanding | 758.16 | 336.1 | 168.28 | 108.0 | 69.14 | 65.68 | |
Income Quality | 0.71 | 1.37 | (2.64) | 0.78 | 1.66 | 1.74 | |
Roe | (0.36) | (0.0483) | 0.0345 | 0.0871 | 0.0732 | 0.0769 | |
Ev To Operating Cash Flow | (7.82) | (68.24) | (25.44) | 24.06 | 9.64 | 10.12 | |
Pe Ratio | (4.91) | (42.04) | 51.34 | 12.86 | 9.51 | 9.99 | |
Return On Tangible Assets | (0.25) | (0.0336) | 0.0184 | 0.0491 | 0.0416 | 0.0437 | |
Ev To Free Cash Flow | (4.02) | (4.31) | (7.18) | (29.45) | 32.03 | 33.63 | |
Earnings Yield | (0.13) | (0.2) | (0.0238) | 0.0195 | 0.0778 | 0.11 | |
Net Debt To E B I T D A | (0.56) | 3.95 | 3.8 | 2.63 | 2.75 | 1.57 | |
Current Ratio | 3.03 | 2.82 | 3.46 | 2.44 | 2.5 | 4.92 | |
Tangible Book Value Per Share | 0.54 | 0.84 | 0.76 | 0.89 | 0.98 | 0.56 | |
Receivables Turnover | 8.26 | 5.73 | 4.16 | 5.41 | 6.27 | 3.78 | |
Graham Number | 1.71 | 1.53 | 0.87 | 0.67 | 1.25 | 0.88 | |
Shareholders Equity Per Share | 0.54 | 0.84 | 0.76 | 0.89 | 0.98 | 0.56 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.